Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bristol Myers Squibb
Biotech
BMS reports phase 3 win in multiple myeloma
With the study continuing to evaluate survival endpoints, it is unclear whether the drugmaker has the evidence needed to seek approval from the FDA.
Nick Paul Taylor
Sep 23, 2025 8:20am
CatalYm C-suite shake-up sees 4 new faces, 3 departures
Sep 15, 2025 10:53am
Sanofi becomes latest pharma to hold fire on UK R&D investments
Sep 15, 2025 10:14am
BioNTech, BMS tout first global data for PD-L1xVEGF drug in SCLC
Sep 8, 2025 11:00am
Career oncologist makes Big Pharma leap to BMS—Chutes & Ladders
Aug 22, 2025 8:30am
Fierce Pharma
BMS touts commercial execution, reckons with clinical setbacks
Jul 31, 2025 11:10am
